New-to-Houston concept tosses salad-making robots into the mix with rapid expansion

Now vending

The Salad Station and Chowbotics have teamed up to bring a salad-making vending machine to multiple locations across Houston. Courtesy of The Salad Station

A healthy foods concept has selected Houston as its next spot to bring its salad-making robot — aptly named Sally. The Salad Station, a Louisiana-based restaurant group, has partnered with California-based Chowbotics to bring salad-making vending machines to Houstonians.

Chowbotics invented Sally, which serves customizable, made-to-order salads, snacks, breakfast bowls, and grain bowls. Scott Henderson, founder and president of The Salad Station, tells InnovationMap that the discussion with Chowbotics about being the company's operational manager started in 2018.

"In seven states, from Texas to Florida, The Salad Station does operations for Sally the robot," says Henderson. "We both have a passion for bringing fresh products to people as many hours of the day as possible."

Henderson tells InnovationMap that he saw potential for the robot to increase opportunities for the chain's franchisees, increasing the amount of locations one person could own.

"We started looking at locations for Sally the robot and just in the Texas Medical Center alone, we feel like it could be 60 to 80 placements," says Henderson.

Due to the massive potential, The Salad Station entered into a partnership with Houston-based RoboFresh as the group's commissary to bring in more than 100 robots by 2022. Henderson tells InnovationMap that there will be 10 salad-making robots in the Texas Medical Center by 2020.

According to Henderson, the robot holds 22 unique ingredients, including two different lettuces, six topping options, and a dressing. The customer is able to customize their ingredients to create the salad of their choice. Payment is completed by credit card or Apple Pay, with most salads costing $7 to $8.

Henderson tells InnovationMap that the number one question they are asked at salad robot facilities is how the machine's ingredients stay fresh.

"We service the machines, at a minimum, twice a day, everyday," says Henderson. "Every morning and afternoon, we have people that go to the robots to bring fresh ingredients and to sanitize the outside of the machine."

Each ingredient is loaded in an airtight container, Henderson says.

"So, from the prepping in our Salad Station restaurants to delivering and installing it, there is no touch of product," says Henderson.

Henderson tells InnovationMap that each canister has an expiration date. For example, the expiration date on spinach is two days, so if the ingredient is not sold within that time frame, it no longer shows an option for the customer.

"Anytime the robot goes over 41 degrees for more than five minutes it disables itself, so customers cannot use the machine until we come back on site and change out the ingredients," says Henderson, adding that the robot maintains a consistent temperature of 34 degrees, keeping produce fresh and crisp.

The salad vending machines are just the beginning of growth in the Space City. The Salad Station is expanding into the Houston area with their first local brick and mortar location in Webster. In addition to the new opening, the franchise is expected to open additional locations across the greater Houston area in the next few years.

"That's where we're at for Texas, we're searching for local people, mainly in the Houston surrounding areas, that want to own their own business," says Henderson.

He adds that he believes the company's family-friendly values and hours will draw in more individuals to help open franchise locations of the fresh food chain.

The Salad Station was founded by Scott Henderson and his mother and business partner Cindy Henderson in 2012, the first store opening in Hammond, LA. Henderson tells InnovationMap that he started franchising the concept in 2014 and locating partners in nearby states to bring The Salad Station to new markets. The restaurant group currently has locations in Louisiana, Mississippi, Alabama, and Florida.

Johnmike Heroman, the head of franchise development at The Salad Station, tells InnovationMap that the chain is currently looking for potential franchise owners in the Houston area and feedback on placement options for Sally's next location.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston billionaire Tilman Fertitta nominated as ambassador to Italy

foreign affairs

Houston billionaire and Rockets owner Tilman Fertitta has been nominated to serve as the United States ambassador to Italy, according to U.S. President-elect Donald Trump.

On Saturday, Trump sent the following statement via Truth Social Post:

"I am pleased to announce that Tilman J. Fertitta has been nominated to serve as the United States Ambassador to Italy. Tilman is an accomplished businessman, who has founded and built one of our Country's premier entertainment and real estate companies, employing approximately 50,000 Americans. Tilman has a long history of giving back to the community through numerous philanthropic initiatives, which include children's charities, Law Enforcement, and the medical community. Additionally, Tilman is the longest serving Chairman of the Board of Regents for the University of Houston. He also owns the Houston Rockets Basketball Team. Congratulations to Tilman, and his remarkable family!"

Fertitta, 67, also is the chairman, CEO, and president of Landry's Inc. and the chairman of the University of Houston's board of regents.

"It is an honor to be nominated to serve my country as ambassador to Italy and I look forward to the process ahead. Italy is such an extraordinary country with its wonderful people, culture, and history and its strategic importance to The United States of America," Fertitta said.

---

Read the full story on CultureMap's news partner, ABC13.com.

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

Houston biotech biz to merge with public co., set local HQ

big deal

Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters.

Tvardi is a clinical-stage biopharmaceutical company that focuses on the development of novel, oral, and small molecule therapies that target STAT3 to treat fibrosis-driven diseases. Tvardi will merge with a wholly owned subsidiary of Cara.

Once complete, the pre-merger Cara Therapeutics stockholders are expected to own approximately 17 percent of the combined company and pre-merger Tvardi Therapeutics investors are expected to own 83 percent of the combined company. Prior to adjustment from the issuance of the shares in the recently completed Tvardi financing and assuming Cara, which went public in 2014, has net cash at closing of between $22.9 million and $23.1 million with the percentage of the combined company that pre-merger Cara stockholders and pre-merger Tvardi stockholders will own upon the closing of the merger, which is subject to further adjustment if Cara’s net cash balance falls outside of the range.

“As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs,” Imran Alibhai, CEO of Tvardi Therapeutics, says in a news release.

Also, Tvardi has completed an approximately $28 million private financing from a syndicate of new and existing institutional investors. With the cash from both companies at closing and the proceeds of this financing, the post-merger company plans to have cash to fund its operating expenses and capital expenditure requirements into the second half of 2026.

“I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases,” Alibhai continues.

In 2021, Tvardi emerged from stealth and closed a $74 million series B funding round led by New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

View All Listings